Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881159 | 0.91 | CCR5 (0.59) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL3874242 | 0.83 | CCR5 (0.71) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL4581898 | 0.81 | CCR5 (0.56) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL13714539 | 0.80 | CCR5 (0.65) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL3873171 | 0.78 | CCR5 (0.59) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL30529985 | 0.77 | CCR5 (0.90) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL3874247 | 0.77 | CCR5 (0.90) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL5078759 | 0.75 | CCR5 (0.51) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL174295 | 0.75 | CCR5 (0.78) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 | |
| SCHEMBL174296 | 0.75 | CCR5 (0.78) | CCR5CYP3A4ADRA2ACYP2C9KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368460-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040067977-A1 | Tropane derivatives useful in therapy | PFIZER, INC. | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067977-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | CCR5 385/4885CYP3A4 246/4885ADRA2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.